Vaxart reported 12-month topline safety data from a 400-participant sentinel cohort in its Phase 2b trial of an oral COVID-19 vaccine. No vaccine-related serious adverse events or severe side effects were observed in participants receiving either Vaxart's oral pill vaccine or an approved mRNA vaccine. Common side effects for the oral vaccine included fatigue and headache, while the mRNA vaccine caused more injection site reactions. Full study results from about 5,400 participants are expected in 2027, which will provide more comprehensive safety and efficacy data. This progress supports Vaxart's oral vaccine platform and its potential as a needle-free COVID-19 vaccine alternative.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
